T0	Participants 95 226	asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL):
T1	Participants 424 545	asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
T2	Participants 733 840	patients were randomly assigned (1:1) to receive enzalutamide 160 mg/day (n=872) or placebo (n=845) orally.
T3	Participants 3446 3530	occurrence of first skeletal-related event in chemotherapy-naive men with metastatic